Precision Lung Cancer Logo

Day One: Monday October 29, 2018

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Lung Cancer Immunotherapy

8:30

Beyond PD-1 and CTLA-4: targeting innate and adaptive immune checkpoints


Catherine Sabatos-Peyton

Director, Immuno-Oncology


Novartis

9:00

What can be done to improve the odds in Immunotherapy Trials

Claudia Lebedinsky
Vice President, Clinical Development

 

 

Constellation Pharmaceuticals

 

9:30

Novel Clinical Trial Designs to Explore Immunotherapy Combinations

 

Edward Cha

Medical Director, Cancer Immunotherapy Franchise

 

Genentech

10:00

Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology

 

Mark Paris

Associate Director, Translational Applications

 

Mitra Biotech

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:30

Neoantigen-specific T cell responses in NSCLC patients profiled using ATLAS™ reveals stimulatory and inhibitory neoantigens that may impact immunotherapy outcomes?

 

Jessica Baker Flechtner

Chief Scientific Officer

Genocea

12:00

Percutaneous Immuno-Oncolytic Drug Delivery Platform, Delivery Study

 

Katelyn Perkins

Program Manager,

Alcyone

LUNCH & NETWORKING

12:15

1:00

Novel EGF-Depleting Immunotherapy for Lung Cancer

 

Doug Plessinger

Chief Clinical & Scientific Development Officer

 

Roswell Park Comprehensive Cancer Center

1:30

Design and Synthesis of Novel Tubulysin Payloads and Site Specific Antibody Drug Conjugates Overcoming In-Vivo Acetate Liability.

 

Carolyn Leverett

Principal Scientist

 

Pfizer

 

2:00

Reprogramming Tumor-Associated Myeloid Cells by Targeting PI3K-gamma with IPI-549

 

Jeff Kutok

Chief Scientific Officer


Infinity Pharmaceuticals

AFTERNOON REFRESHMENTS & NETWORKING

2:30

3:00

The Clinical Effectiveness of an Immuno-oncology Combination Utilizing a Multi-antigen T-cell Activation Platform with Immune Checkpoint Inhibition

 

Jeff Hutchins

Chief Scientific Officer, SVP, Pre-clinical Research

Heat Biologics

3:30

ImmunoSTATs : a novel biologic platform to enable antigen-specific immunotherapies

 

 

Anish Suri

Chief Scientific Officer

 

Cue Biopharma

4:00

Activating Immune Responses in Cancer

 

Sia Anagnostou

Senior Director, Corporate Development

Immunomic Therapeutics

 

ROUND TABLE DISCUSSIONS

4:30

Roundtable Topics:

Preclinical Considerations in Cancer Drug R&D

Translational Considerations in Cancer Drug R&D

Clinical Considerations in Cancer Drug R&D

Moderator:

Moderator:

Moderator:

Lawrence Thomas

Executive Director, Preclinical R&D

 

Celldex Therapeutics

TBA

TBA

DRINKS RECEPTION & NETWORKING

5:00

VIEW NEXT DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2018 | All content produced by: neo-synth ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF